Mortality (all‐cause) · patients with chronic obstructive pulmonary disease
It is very uncertain whether once‐daily ICS/LABA combined inhalers changes mortality (all‐cause) compared with once‐daily LAMA (very low certainty).
1 finding from 1 review
Mortality (all‐cause) · acute exacerbations of chronic obstructive pulmonary disease
Action plan showed no clear difference in mortality (all‐cause) compared with usual care (moderate certainty).
1 finding from 1 review
Mortality (all‐cause) · patients with chronic obstructive pulmonary disease
Tiotropium + LABA/ICS combination showed no clear difference in mortality (all‐cause) compared with tiotropium (moderate certainty).
1 finding from 1 review
Mortality (all‐cause) · chronic obstructive pulmonary disease (COPD). Participants in included studies had an average baseline FEV1 of around 40% predicted and…
Tiotropium showed no clear difference in mortality (all‐cause) compared with ipratropium (moderate certainty).
1 finding from 1 review
Mortality (all‐cause) · patients with stable chronic obstructive pulmonary disease
Aclidinium bromide showed no clear difference in mortality (all‐cause) compared with placebo (low certainty).
1 finding from 1 review
Mortality (all‐cause) · patients with stable chronic obstructive pulmonary disease
1 finding from 1 review
Mortality (all‐cause) · patients with chronic obstructive pulmonary disease
Long‐acting beta2‐agonists showed no clear difference in mortality (all‐cause) compared with placebo (moderate certainty).
1 finding from 1 review
Mortality (all‐cause) · patients with stable chronic obstructive pulmonary disease and > 10 pack years smoking history
It is very uncertain whether tiotropium changes mortality (all‐cause) compared with long‐acting beta‐agonists (very low certainty).
1 finding from 1 review
Long‐term all‐cause mortality · people with low‐risk acute pulmonary embolism
Outpatient showed no clear difference in long‐term all‐cause mortality compared with inpatient treatment (low certainty).
1 finding from 1 review
Short‐term all‐cause mortality · people with low‐risk acute pulmonary embolism
2 findings from 1 review
Mortality within the longest · Children having heart surgery with cardiopulmonary bypass
Glucocorticoid showed no clear difference in all‐cause mortality at longest compared with placebo (moderate certainty).
1 finding from 1 review
Anti‐cytokine, all‐cause mortality ‐ uncertain risk of bias · patients with chronic obstructive pulmonary disease
It is very uncertain whether multi‐component interventions (with telehealth as a component of care) changes mortality (all‐cause) overall analysis compared with usual care (very low certainty).
1 finding from 1 review
All‐cause mortality · general population over 2 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · general population over 2 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · general population over 2 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · general population
1 finding from 1 review
no estimate extracted
Studies not reported
Low
All‐cause mortality · general population
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
All‐cause mortality · general population
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
All‐cause mortality · General population, as well as age‐specific subgroups (< 1 year; < 14 years; > 65 years)
1 finding from 1 review
no estimate extracted
Studies not reported
Low
All‐cause mortality · general population including those at moderate to high risk of CVD, mean age between 30 and 75
Systematic screening showed no clear difference in all‐cause mortality compared with no/opportunistic screening (low certainty).
1 finding from 1 review